Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-25-038616·CUMBERLAND PHARMACEUTICALS INC
Schedule 13G ownership disclosure
Cumberland Pharmaceuticals, Inc.
Common Stock, no par value · CUSIP: 230770109
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Integrated Core Strategies (US) LLC
Shares: 809,897.00 · Class: 5.8%
- Millennium Management LLC
Shares: 809,897.00 · Class: 5.8%
- Millennium Group Management LLC
Shares: 809,897.00 · Class: 5.8%
- Israel A. Englander
Shares: 809,897.00 · Class: 5.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-038616
- Form type
- SCHEDULE 13G/A
- Filer
- CUMBERLAND PHARMACEUTICALS INC
- CIK
- CIK 1087294
- Filed
- Apr 24, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership